PCM Trials Joins DTRA in Response to Growing Demand for Decentralized Clinical Trials

PCM Trials Joins DTRA in Response to Growing Demand for Decentralized Clinical Trials

DENVER (May 11, 2022) — PCM Trials has joined the Decentralized Trials & Research Alliance (DTRA), an alliance of life sciences and healthcare organizations that seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials (DCTs) and clinical research. According to Greg Austin, President of PCM Trials, the decision to join DTRA was prompted due to increased demand for DCTs throughout the pharmaceutical industry.

Since 2020, PCM Trials has seen tremendous growth in the number of RFPs it receives for remote trials to be conducted by its Certified Mobile Research Nurses (CMRNs), making PCM Trials one of the largest independent providers of mobile research.

“We’re pleased to contribute to DTRA’s mission to accelerate decentralized clinical trials,” says Greg Austin, President of PCM Trials.  “We look forward to collaborating with industry stakeholders to reduce barriers to participation in clinical trials and support recruitment, retention and diversity.” 

The DTRA launched in late 2020 to unite industry stakeholders, including healthcare companies, regulators, patient groups and research organizations, to make clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research.

Experts estimate that COVID-19 may set back non-pandemic clinical trials by several years due to prospective patients’ inability or reluctance to schedule visits at physical research locations. Decentralized approaches to conducting research facilitate participation by a more diverse patient population and could ease COVID-19-imposed difficulties for both patients and clinical researchers. Inclusion of representative patient populations in clinical trials by race, age and geographic location has long been an operational challenge.  COVID-19 has amplified the disparities and inclusion biases that have become hurdles for potential trial participants.

“By joining and contributing to DTRA’s mission, PCM Trials is demonstrating its industry leadership and commitment to drive change,” said Craig Lipset, DTRA co-convener, clinical innovation advisor and a pioneer in decentralized clinical trials.  “We have a responsibility to advance the health of people with unmet medical needs, and by convening stakeholders from pharma companies, DCT providers, regulators, technology leaders and patient communities, we can remove remaining barriers to adoption and impact patients today.”

About PCM Trials

PCM Trials is leading the global shift toward decentralized clinical trials by bringing clinical research to patients, wherever and whenever it is most convenient for them. PCM Trials directly recruits, trains, certifies, and manages Certified Mobile Research Nurses (CMRNs) to ensure that each visit meets the highest standards for data quality and patient experience.  By reducing the barriers to participation, PCM Trials’ mobile nurses support study recruitment, retention, adherence, and diversity. PCM Trials is an independent company headquartered in Denver, Colorado, with European operations based out of the UK, and has conducted more quality mobile research visits than any specialized providers in Europe, North America, and Asia Pacific. Learn more at www.pcmtrials.com. 

About DTRA

The Decentralized Trials & Research Alliance (DTRA) was convened to enable collaboration of stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare through education and research. It works to make research participation accessible to everyone, enabled by the consistent, widespread adoption of appropriate decentralized research methods. Follow DTRA on Twitter and LinkedIn for more information.